These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15794499)

  • 1. Darbepoetin alfa in anemia management: a vital role in cancer care.
    Boccia R
    J Support Oncol; 2005; 3(2 Suppl 1):3-5. PubMed ID: 15794499
    [No Abstract]   [Full Text] [Related]  

  • 2. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R; Smith R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
    Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 8. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG; Natale JJ
    Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
    Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):1-2. PubMed ID: 11308267
    [No Abstract]   [Full Text] [Related]  

  • 10. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
    Pirker R
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Waltzman RJ
    Cancer; 2004 Apr; 100(7):1545-6; author reply 1546. PubMed ID: 15042691
    [No Abstract]   [Full Text] [Related]  

  • 14. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
    Vansteenkiste J; Wauters I
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy".
    Nowrousian MR
    Oncologist; 2006 May; 11(5):535-6; author reply 536-7. PubMed ID: 16720859
    [No Abstract]   [Full Text] [Related]  

  • 19. The emerging role of darbepoetin alfa in the management of patients with cancer.
    Gordon MS
    J Support Oncol; 2004; 2(2 Suppl 2):2-3. PubMed ID: 16108417
    [No Abstract]   [Full Text] [Related]  

  • 20. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.